Chongyang Ding, Dr

Department of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, China (People's Republic)

N/A

Poster(s):

• 1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort